Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: J Reprod Immunol. 2007 Oct 24;78(1):58–67. doi: 10.1016/j.jri.2007.08.004

Fig. 2.

Fig. 2

Survival of mice following passive transfer of gD-specific mAb. A, Groups of 10–20 mice received PBS, or either 50µg or 1.0µg 10E4.2G2a, prior to ivag inoculation with 5×103 PFU HSV-2. Survival curves are marked to denote statistical significance as follows: **p< 0.0001 compared to PBS-treated B6; ψp < 0.016 compared to FcγR−/− Ab recipients; and *p < 0.04 compared to PBS-treated B6 mice by Logrank test. Groups of 15µMT and Rag 1 −/− mice (B) or B6 and FcγR−/− mice (C) were given 50µg 10E4.2G2a or PBS 2 days before ivag inoculation with 5×103 PFU HSV-2. Results shown are from representative experiments of two performed. Survival curves significantly different than PBS controls are marked with an asterisk (p<0.001, Logrank test). D, HSV-2 titers in the genital tracts from groups of 15 B6 mAb recipients, FcγR−/− mAb recipients or B6 PBS-treated controls were quantified on the indicated days after HSV-2 inoculation. Marked values are significantly different compared to PBS-treated controls (*p < 0.001; **p < 0.01, ANOVA).